National and Kapodistrian University of Athens
Επιδημιολογική μελέτη των πλασμιδιακών μηχανισμών αντοχής στις κινολόνες σε εντεροβακτηριακά που απομονώνονται από ασθενείς του Πανεπιστημιακού Γενικού Νοσοκομείου ΑΤΤΙΚΟΝ
Abstract
dc:descriptionABSTRACTQuinolone resistance in Gram-negative bacteria is mostly mediated by point mutations in the quinolone resistance-determining regions (QRDRs) of the gyrase and topoisomerase IV genes, leading to target modification. Additionally, three plasmid-mediated quinolone resistance (PMQR) mechanisms have been described since 1998: (i) Qnr peptides, capable of protecting DNA gyrase and Topoisomerase IV from quinolones, (ii) Aac(6’)-Ib-cr aminoglycoside acetyltranferase, modifying quinolones with a piperazinyl substituent (norfloxacin and ciprofloxacin) and (iii) the quinolone efflux pumps (QepA and OqxA & B).PMQR has been found in clinical and environmental isolates around the world and appears to be spreading.. The plasmid-mediated mechanisms provide only low-level resistance that by itself does not exceed the clinical breakpoint established by EUCAST for susceptibility. Nonetheless, the presence of PMQR determinants in isolates with additional chromosome-borne mechanism(s) facilitates higher-level of quinolone resistance, and their co-exhistance with other resistance determinants especially genes coding for β-lactamases including ESBLs and carbapenemases, located in the same conjugative plasmids, indicates selection and spreading of multidrug-resistance due to excessive use of quinolones.The aim of this study was to investigate the prevalence of plasmid-mediated quinolone resistance (PMQR) genes in an unselected collection of Gram-negative strains isolated from hospitalized patients over an 18-month period in a laboratory affiliated to a University General Hospital in Athens. Additionally, to investigate their coexistence progeny resistant to other antimicrobial groups such as beta-lactamases and carvapenemases, in the same conjugative plasmids. Finally, to assess the impact of the PMQR, on the in vitro activity of ciprofloxacin and levofloxacin.We studied 96 strains of Gram-negative strains isolated from bacteremia, and 340 E. coli strains (n = 185) and K.pneumoniae (n = 155) isolated from urinary tract infections, pus or bronchial secretions in the Infectious Diseases Reaserch Laboratory of the 4th Department of Internal Medicine of University General Hospital 'Attikon', the period October 2008 to March 2010. All isolates were resistant to nalidixic acid and susceptible or resistant to fluoroquinolones. Only one isolate per patient was included in the study.We found that the prevalence of PMQR genes was 17.2% among all strains tested and 7.3% among unselected bloodstream Gram-negative isolates in our institution, indicating that plasmid-mediated quinolone resistance in Greece, may be more frequent than previously suggested. Also, for the first time, to our knowledge, the co-existence of qnrS1 and aac(6’)-Ib-cr in the same plasmid was detected.The results of our cloning experiments are in agreement with the current knowledge that a single PMQR determinant by itself provides only a low level of resistance to quinolones comparable to that provided by a first-step mutation in DNA gyrase. Also, we have seen that qnrS1 is responsible for a lower level of resistance as compared to qnrA1 or qnrB2 when expressed in laboratory strains. Additionally, PMQR genes and/or mutations in QRDR may increase the MIC above the susceptibility breakpoint . Nonetheless, the most important consequence of the dissemination of PMQR-carrying plasmids is their role in facilitating the selection of higher-level quinolone-resistant mutants and the co-selection of other resistance determinants residing on the same plasmid, especially genes coding for β-lactamases including ESBLs and carbapenemases . MPC evaluation in clinical and laboratory isolates confirmed the contribution of PMQR determinants in widening the MSW of both ciprofloxacin and levofloxacin, for most of the isolates tested, to levels above peak serum concentrations attained during drug therapy, rendering the attainment of AUC/MPC criterion impossible to meet by conventional dosing . Under these circumstances, quinolone monotherapy will select for high-level quinolone resistance.Time-kill assays undertaken using the quinolone-susceptible clinical and laboratory isolates confirmed that the presence of PMQR determinants may occasionally compromise the bactericidal activity of ciprofloxacin and levofloxacin, especially when expressed in E.cloacae, S.maltophilia or K.pneumoniae and when more than one PMQR determinants coexist.Finally, inoculum effect evaluation in the present study revealed that the MICs of all clinical isolates increased above the susceptibility breakpoint for both quinolones tested in the presence of high inoculum suggesting that, in the context of a clinical infection, PMQR-harboring pathogens may fail quinolone treatment. In summary, we have found that the prevalence of PMQR genes in Gram-negative isolates is higher than previously suggested in Greece. The PMQR can compromise the in vitro efficacy of quinolones if expressed in a favorable genetic background, they can enlarge the MSW of these agents facilitating the selection of higher-resistant mutants and they may contribute to clinical failure in the setting of high-inoculum infections. Empirical treatment with quinolones must be used with caution and must be avoided in infections due to nalidixic acid resistant isolates or when exhibit an MIC≥0.25mg/L to either ciprofloxacin or levofloxacin.PMQR determinants represent an actual threat that may go unnoticed. There are no phenotypic markers that indicate their presence, therefore, it is necessary to monitor for their spread. Analysis of plasmids and genetic structures on which PMQR determinants are mounted is needed in order to better understand their successful dissemination.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Margaritis, Athanasios
- Μαργαρίτης, Αθανάσιος
Subjects
dc:subject × 14Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40588